SAN DIEGO REGULATORY AFFAIRS NETWORK January 20, 2005 SARBANES-OXLEY Challenges for FDA-Regulated Companies Michael A. Swit, Esq. Vice President, Life.

Slides:



Advertisements
Similar presentations
Building on Our Core Values Building on Our Core Values © 2003 by the AICPA The Sarbanes-Oxley Act.
Advertisements

Chapter 19-Securities Securities Regulation Public Offerings of New Securities. zWhen “going public” there are many different types of securities that.
Keeping Energy Companies Out of Trouble- Dealing with the SEC Ethical Dilemmas, and Avoiding Criminal Liability Charles Parker Locke Liddell & Sapp LLP.
Internal Audit Awareness
Process of CG in Egypt Mohamed Omran Vice Chairman Cairo & Alexandria Stock Exchanges December, 13 th 2006.
Chapter Twelve Financial Reporting and the Securities and Exchange Commission Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction.
IS3350 Security Issues in Legal Context
ELECTION AND QUALIFICATIONS OF DIRECTORS Robert D. Strahota, Assistant Director * SEC Office of International Affairs Prepared for the panel on Improving.
Copyright © 2011 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin Chapter Six Legal and Regulatory Obligations in an Ethical Framework.
Sarbanes-Oxley Act. 2 What Is It? Act passed by Congress in response to the recent and continuing corporate scandals. Signed into law July 30, Established.
Fraud and SOX Compliance McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
Seminar in Accounting & Society SOX – Section 404 April 23, 2008.
Food & Drug Law Institute Annual Conference Washington, D.C. April 22, 2009 Michael A. Swit, Esq. Vice President Drug Safety –Perspectives on Industry’s.
E-Commerce: Legal and Practical Issues Legal Issues: Security – December 2, 2005 Stephen M. Foxman Philadelphia.
REGULATORY AFFAIRS PROFESSIONALS SOCIETY HORIZONS CONFERENCE & EXHIBITION March 30, 2006 San Diego, California Crisis Management & FDA-Regulated Firms.
WELCOME Annual Meeting & Compliance Seminar. Code of Conduct - Impact on Corporate Culture by Andy Greenstein Knight Capital Group, Inc.
1 Crisis Management for the Regulatory Professional.
© 2004 Ceridian Corporation. All rights reserved. Corporate Integrity and The Sarbanes-Oxley Act Victoria Nemerson Vice President Compliance, Ceridian.
Sarbanes-Oxley Act a.k.a. “SOX”
Supplier Ethics: Program Checklist
Building a Compliance Risk Monitoring Program HCCA Compliance Institute New OrleansApril 19, 2005 Lois Dehls Cornell, Esq. Assistant Vice President, Deputy.
Data Protection Paul Veysey & Bethan Walsh. Introduction Data Protection is about protecting people by responsibly managing their data in ways they expect.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
© Copyright 2012 Pearson Education. All Rights Reserved. Chapter 10 Fraud & Internal Control ACCOUNTING INFORMATION SYSTEMS The Crossroads of Accounting.
Internal Auditing and Outsourcing
© 2005 West Legal Studies in Business, a division of Thompson Learning. All Rights Reserved.1 PowerPoint Slides to Accompany The Legal, Ethical, and International.
FDA Regulatory Considerations in Launching Products Michael A. Swit, Esq. Vice President, Life Sciences WITI (Women In Technology International) San Diego.
6 Months Since Sarbanes/Oxley 259 criminal actions in FY2002 by 30 different U.S. Attorney's Offices and DOJ for securities-related offenses or obstruction.
Audit Legal Environment
Food & Drug Law Institute Conference on Products Liability For FDA Regulated Products January 26, 2005 Recalls: The First Smoke of A Mass Tort Overview.
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
Copyright © 2008 by West Legal Studies in Business A Division of Thomson Learning Chapter 46 Securities Regulation Twomey Jennings Anderson’s Business.
Securities Fraud Material misrepresentation. Unfairness as fraud? Kirby Lumber Santa Fe Minority (Green) 95%5%
Implementation Issues of Sarbanes-Oxley CASE Presentation September 23, 2004 By Denise Farnan.
The International Pharmaceutical Compliance Summit on Medical Affairs, Clinical Trials, Safety and Publication Philadelphia, Pennsylvania March 31, 2005.
v2 Climate Change Disclosure for Canadian Public Companies Barbara Hendrickson Corporate Reporting: Climate Change & Related Environmental Disclosures.
Summary of the Investor Protection, Auditor Reform, and Transparency Act of 2002 (Sarbanes-Oxley Act)
Corporate Responsibility and Compliance After Enron and Sarbanes-Oxley 6th National Congress on Health Care Compliance February 2003 John Bentivoglio
1 Today’s Presentation Sarbanes Oxley and Financial Reporting An NSTAR Perspective.
By: 1. Kenneth A. Kim John R. Nofsinger And 2. A. C. Fernando.
By: 1. Kenneth A. Kim John R. Nofsinger And 2. A. C. Fernando.
Risk Issues for the Board Presented By: Dr. Cesar G. Saldaña, Ph. D. Founding Fellow, ICD.
U.S. Environmental Protection Agency Office of Criminal Enforcement, Forensics, & Training Jeffrey Denny, Resident Agent in Charge Indianapolis Resident.
Information Security Governance and Risk Chapter 2 Part 3 Pages 100 to 141.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
McGraw-Hill/Irwin Copyright © 2011 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 16 Regulation of Securities, Corporate Governance, and.
REGULATORY AFFAIRS PROFESSIONALS SOCIETY WEST COAST CONFERENCE & EXHIBITION March 22, 2005 Corporate Responsibility Issues for Regulatory Affairs Professionals.
Unit 5 Midterm Review. What are some of the components of the ABA?
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Nutter McClennen & Fish LLP World Trade Center West 155 Seaport Boulevard Boston, Massachusetts Telephone Massachusetts.
OHS Seminar DO THE TIME – avoid the crime! Miles Crawley 8 June 2007.
Managing Sponsor/Investigator Relationships 5 th National Conference on Managing Legal Risks in Structuring and Conducting Clinical Trials American Conference.
FDLI 49 th Annual Conference Washington, D.C. April 7, 2006 THE FUTURE OF COMPLIANCE GOVERNANCE Michael A. Swit, Esq. Vice President, Life Sciences.
Understanding Business Ethics 2 nd Edition © 2014 SAGE Publications, Inc. Chapter 13 Evaluating Corporate Ethics Understanding Business Ethics Stanwick.
Copyright © 2010 Pearson Education, Inc. Publishing as Prentice Hall.17-1 Chapter 17 Investor Protection and E- Securities Transactions.
HARRIS PROPRIETARY 1 assuredcommunications™ NCMA Each of Medco Health’s False Claims Was “Knowingly Submitted” Because Medco Health Had No Effective Corporate.
Chapter 41 Corporations: Securities and Investor Protection McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved.
REGULATORY AFFAIRS PROFESSIONALS SOCIETY HORIZONS CONFERENCE & EXHIBITION Crisis Management for the Regulatory Professional.
Securities Fraud Material misrepresentation Unfairness as fraud? Kirby Lumber Santa Fe Minority (Green) 95%5%
1 HOW THE ORGANIZATIONAL SENTENCING GUIDELINES AFFECT HOW THE ORGANIZATIONAL SENTENCING GUIDELINES AFFECT COMPLIANCE AND ETHICS PROGRAMS FIFTH ANNUAL.
Sarbanes-Oxley Act a.k.a. “SOX” Georgia CTAE Resource Network Curriculum Office, February 2009 To accompany curriculum for the Georgia Peach State Career.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Building on Our Core Values Building on Our Core Values © 2003 by the AICPA The Sarbanes-Oxley Act.
May 5, 2016 May 5, Reporting obligations for  Investment banks,  Stockbrokers and dealers  FM and Investment advisers 2. Publication financial.
 The U.S. Securities and Exchange Commission (SEC) oversees the key participants in the securities world.  Concerned with promoting disclosure of important.
Summary of the Investor Protection, Auditor Reform, and Transparency Act of 2002 (Sarbanes-Oxley Act)
Privileged Information: Confidentiality and Disclosure
The Sarbanes-Oxley Act
Board of Directors Roles and Responsibilities
Compliance, Ethics, and Audit
Presentation transcript:

SAN DIEGO REGULATORY AFFAIRS NETWORK January 20, 2005 SARBANES-OXLEY Challenges for FDA-Regulated Companies Michael A. Swit, Esq. Vice President, Life Sciences

Caveat I am an FDA regulatory attorney, not an SEC lawyer But, this could happen to you … –My first day as General Counsel of Par Pharmaceutical, a publicly-traded company, the CFO says to me, “we have this situation [can’t tell you what it was], do we need to disclose this? –Can’t tell you my answer either -- but there was no press release that day or for a number of days thereafter until we sufficiently completed an internal investigation

Agency Missions FDA –Protect public health –Review and approve products for safety and effectiveness –No overt economic duty –Regulates disclosures only to extent they are labeling or advertising SEC –Ensure market activity is done on a level playing field –No public health duty –Regulates disclosures in a wide variety of ways Technical compliance Fraud

Duties FDA-Regulated Firms –Lawfully market safe and effective products that are not adulterated or misbranded –U.S. v. Park – responsible corporate agents in a position to prevent a violation can be criminally liable for FDA violations event w/o intent or knowledge Duty to seek out potential violations –No affirmative duty to publicly disclose “material” information –Affirmative duties to disclose to FDA Field Alerts – – mix-ups or specifications failures Stability commitments

Duties … SEC Regulated Firms –Very detailed disclosure requirements –But, absent an affirmative duty to disclose, silence is not misleading (except may have a duty to correct prior disclosures now learned to be wrong & if you want to trade, must disclose) Question – when are there affirmative duties to disclose under SEC law? Answer – focus is usually “materiality” of the event -- we will explore some examples later in the FDA context –No overt duty to investigate corporate problems; however, under SOX, now are multiple duties on a company to have adequate procedures to ensure accuracy of public reports Stock Exchanges – NYSE ♦ NASDAQ –Have more affirmative duties to disclose – usually done via press release

Duties … General Corporate Law – –No overt duty to disclose material information to public –Related duties impacting corporate responsibility Delaware law – must have an adequate compliance program to prevent violations and probe to ensure violations did not occur – Caremark (1996) McCall (2001): Columbia/HCA shareholder derivative action against board members; –Directors lose protection of “business judgment” rule and are personally liable for failure to detect and correct violations –Board’s duty of care breached through nonfeasance: failure to investigate items from internal audit

Timing Rules FDA –Annual reports – INDs & NDAs –Field Alerts – 3 “working” days –Adverse Events – Unexpected serious AE -- “as soon as possible,” but no later than 15 calendar days Others – quarterly for first 3 years post-approval; then annually SEC –Annual & quarterly reports – updates since prior –8-K’s – for certain specified and “other events” – supposed to implement SOX "real time issuer disclosure" requirement – within 4 business days of the event

Codes of Ethics SOX – for senior financial officers NYSE & NASDAQ – for whole company FDA –No duty to have a code –Exception – Application Integrity Program – then need one

Record Retention SOX – 7 years FDA – vary – but less than that typically –Caution – record retention beyond required may come back to both help you or haunt you – implement with care

Life Sciences Companies Disclosures and the SEC For a disclosure to be actionable, it usually must be both false or misleading and “material” – thus, these are fact-specific scenarios “Material” – info would have “actual significance in the deliberations of the reasonable shareholder”

Life Sciences Companies Disclosures and the SEC … Forward Looking Statements – –Safe harbor –Must be a “meaningful cautionary” statement – and not omit any key information as well –Only liable if false statement made with actual knowledge of its falsity Predicting FDA approval -- OK to be wrong as long as there was a reasonable basis for the initial prediction –But, contrast if those making the disclosure knew a key undisclosed fact that seriously threatened the predicted approval time –No clear duty to update

Life Sciences Companies Disclosures and the SEC … Adverse Events – must be “statistically significant” to be “material” FDA reports on pending applications – e.g., advance copy of a highly negative FDA staff report to an advisory committee –Depends on what you do with them; beware continuing to make positive statements (Zila & Zenith) –But, just because you get a bad 483 or report on a submitted study, does not mean that a prediction of approval or other statement on a product will be found to be false (Sabratek)

Life Sciences Companies Disclosures and the SEC … Clinical Trial Results – –If disclosure involves an interpretation of the results, will only be actionable if not within the range of reasonable science –No duty to disclose all facts about a study, as long as those selected are done in a reasonable way and any omissions would not render the disclosure “so incomplete as to mislead” –Negative trial results You have a reasonable time to evaluate – until you do, you lack “material information” No overt duty to disclose, except if: –Your officers are trading in the stock –Public statements are misleading if the results are NOT disclosed

Life Sciences Companies Disclosures and the SEC … Pending Investigations and Inspections – duty to disclose – company must look at to the probability and magnitude of a particular sanctions in evaluating if it’s material –Abbott Consent Decree – not material A way to analyze – weigh: –Degree of noncompliance –Likelihood of resulting FDA action –Projected impact of such action on the company

Life Sciences Companies Disclosures and the SEC … Recommendations – –have a prescribed process – and follow it -- for reaching internal consensus on what to publicly disclose on test results so that contrary memos don’t come back to haunt you –Define terms used to describe test results with precision – and in the disclosure document –Be very careful to not infer FDA’s conclusions on a matter – just report actions –Once you’ve made a disclosure about FDA, you have to reevaluate it as time passes and (a) either additional events occur or (b) new SEC reports are required (e.g., quarterly)

Other SOX Statutory Changes Impacting FDA-Regulated Companies 18 U.S.C. -- Criminal code – additions –§ 1519 – crime to destroy, alter or falsify with intent to impede, obstruct or influence –§ 1513 – crime to retaliate against a person who provides information to a law enforcement officer –§1514A – civil action created if retaliation occurs vs. whistleblower in fraud cases involving public cos. –Wire and mail fraud convictions now can garner 20 years prison for single offense

FDA-SEC Cooperation Post-Imclone February 2004 – new ground rules on FDA interacting with SEC –FDA staff now can refer any information they may have about a suspected misstatement by an FDA- regulated public company to FDA General Counsel for review and tender to SEC –Blanket authorization for FDA staff to cooperate with SEC inquiries

Key Internal Procedures Disclosure Committee –Executive –Financial –Legal –Other key components depending on maturity of company Clinical or R&D R.A. and Q.A. Counsel – SEC, Corporate and FDA

A Few Parting Thoughts These are pictures you do not want to see …. –in your newspaper …. –on your local news …. –on the Internet …. or –in FDA regulatory lawyers’ presentations for years to come ….

Ex-Imclone CEO Exits Federal Court After Being Charged with Nine Felony Counts

Ex-Imclone CEO exits federal court after entering guilty plea …

THE RESULT … Pled guilty October 15, 2002 to six counts, including: –Bank fraud –Securities fraud, aka “insider trading” –Conspiracy to obstruct justice, and –Perjury Faced: up to 65 years in prison; millions in fines

THE SENTENCE 7- year 3-month prison sentence –with no parole $3 million fine $1 million in back taxes Where can you find him now? –Schuylkill Federal Correctional Institute in Minersville, Pa. (been there since July 2003)

Let’s Go Back to My First Day at Par Did I have a duty to disclose? –Was the information “material” No – because it had not been investigated –Indeed – premature disclosure can harm the markets as well

Questions? Call, , fax or write: Michael A. Swit, Esq. Vice President, Life Sciences THE WEINBERG GROUP INC. 336 North Pacific Coast Hwy. 101 Suite C Encinitas, CA Phone Fax Cell D.C. Office

For more than twenty years, leading companies have depended on THE WEINBERG GROUP when their products are at risk. Our technical, scientific and regulatory experts deliver the crucial results that get products to market and keep them there.